Serum interleukin-18 and its relationship with subclinical atherosclerosis in systemic lupus erythematosus.
Atherosclerosis
Interleukin-18
Systemic Lupus Erythematosus
Journal
ARYA atherosclerosis
ISSN: 1735-3955
Titre abrégé: ARYA Atheroscler
Pays: Iran
ID NLM: 101487337
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
21
02
2020
accepted:
30
06
2021
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
ppublish
Résumé
Interleukin-18 (IL-18) is a pro-inflammatory and pro-atherogenic factor, and its blood level has shown a direct correlation with atherosclerosis. We aimed to evaluate the serum IL-18 level in patients with systemic lupus erythematosus (SLE) and its relationship with the intima-media thickness (IMT) of the carotid artery in these patients, as an indicator of atherosclerosis. In this cross-sectional study, 60 patients as the patient group and 30 healthy volunteers as the control group [matched sex, age, and body mass index (BMI)] were selected, and their disease status and general data were gathered using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) form. A blood sample was also obtained from all participants to determine the serum level of IL-18 and other metrics, including high-sensitivity C-reactive protein (hs-CRP), cholesterol, triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), anti-double stranded deoxyribonucleic acid (anti-dsDNA), complement 3 (C3), and C4. The IMT of the carotid artery was calculated in both groups. We also evaluated the clinical cardiovascular manifestations. The serum IL-18 levels in patients were significantly higher than in the control group (P ˂ 0.005). It had no significant correlation with disease activity (P = 0.10). The patients with SLE with high IL-18 serum levels (> 280 pg/ml) had higher SLEDAI-2K (P = 0.02) than the patients with a low level (< 280), where 280 was the median of the IL-18 levels. The serum IL-18 level had no significant correlation with the carotid artery IMT. A high level of IL-18 reflects the disease activity, but it was not significantly correlated with subclinical atherosclerosis, denoted by the carotid artery IMT.
Sections du résumé
BACKGROUND
BACKGROUND
Interleukin-18 (IL-18) is a pro-inflammatory and pro-atherogenic factor, and its blood level has shown a direct correlation with atherosclerosis. We aimed to evaluate the serum IL-18 level in patients with systemic lupus erythematosus (SLE) and its relationship with the intima-media thickness (IMT) of the carotid artery in these patients, as an indicator of atherosclerosis.
METHODS
METHODS
In this cross-sectional study, 60 patients as the patient group and 30 healthy volunteers as the control group [matched sex, age, and body mass index (BMI)] were selected, and their disease status and general data were gathered using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) form. A blood sample was also obtained from all participants to determine the serum level of IL-18 and other metrics, including high-sensitivity C-reactive protein (hs-CRP), cholesterol, triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), anti-double stranded deoxyribonucleic acid (anti-dsDNA), complement 3 (C3), and C4. The IMT of the carotid artery was calculated in both groups. We also evaluated the clinical cardiovascular manifestations.
RESULTS
RESULTS
The serum IL-18 levels in patients were significantly higher than in the control group (P ˂ 0.005). It had no significant correlation with disease activity (P = 0.10). The patients with SLE with high IL-18 serum levels (> 280 pg/ml) had higher SLEDAI-2K (P = 0.02) than the patients with a low level (< 280), where 280 was the median of the IL-18 levels. The serum IL-18 level had no significant correlation with the carotid artery IMT.
CONCLUSION
CONCLUSIONS
A high level of IL-18 reflects the disease activity, but it was not significantly correlated with subclinical atherosclerosis, denoted by the carotid artery IMT.
Identifiants
pubmed: 35685451
doi: 10.22122/arya.v17i0.2126
pii: ARYA-17-3-2126
pmc: PMC9145840
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-6Informations de copyright
© 2021 Isfahan Cardiovascular Research Center & Isfahan University of Medical Sciences.
Références
J Cell Mol Med. 2017 May;21(5):993-1012
pubmed: 27878954
Arthritis Res Ther. 2016 Dec 30;18(1):306
pubmed: 28038677
Eur Cytokine Netw. 2010 Dec;21(4):264-71
pubmed: 21126942
BMC Med Genet. 2012 Nov 15;13:107
pubmed: 23153245
J Cardiol. 2015 Jul;66(1):28-35
pubmed: 25475966
Atherosclerosis. 2006 Oct;188(2):450-4
pubmed: 16405895
Lupus. 2019 Apr;28(4):545-554
pubmed: 30857465
Atherosclerosis. 2011 Jul;217(1):227-33
pubmed: 21481392
Arthritis Res Ther. 2018 Feb 08;20(1):27
pubmed: 29422069
Front Immunol. 2018 Jun 07;9:1250
pubmed: 29930551
Sci Rep. 2021 Feb 25;11(1):4707
pubmed: 33633218
J Immunol. 2012 Jul 15;189(2):499; author reply 499-500
pubmed: 22773659
Rheumatology (Oxford). 2006 Sep;45(9):1148-53
pubmed: 16527878
J Nephropathol. 2016 Jan;5(1):28-33
pubmed: 27047807
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2043-9
pubmed: 17626902
Front Med (Lausanne). 2018 Jan 29;4:262
pubmed: 29435447
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1458-62
pubmed: 15860738
Scand J Rheumatol. 2006 Mar-Apr;35(2):128-32
pubmed: 16641047
G Ital Cardiol (Rome). 2006 Sep;7(9):594-603
pubmed: 17128781